Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · April 01, 2024

Outcomes of Fulvestrant, Palbociclib, and Avelumab Treatment After Progression on CDK4/6i and Aromatase Inhibitor Therapy for HR+/HER2− Metastatic Breast Cancer

Journal of Clinical Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer
J. Clin. Oncol 2024 Mar 21;[EPub Ahead of Print], EL Mayer, Y Ren, N Wagle, R Mahtani, C Ma, A DeMichele, M Cristofanilli, J Meisel, KD Miller, Y Abdou, EC Riley, R Qamar, P Sharma, S Reid, N Sinclair, M Faggen, CC Block, N Ko, AH Partridge, WY Chen, M DeMeo, V Attaya, A Okpoebo, J Alberti, Y Liu, E Gauthier, HJ Burstein, MM Regan, SM Tolaney

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading